Jun 15, 2020
Salix Announces Inaugural Salix Gastrointestinal Health Scholars Program Recipients
May 06, 2020
Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation
Mar 20, 2020
Colonoscopy Bowel Preparation Drugs Market to Surpass US$ 2.4 Billion, Globally, by the End of 2027 - Coherent Market Insights
Nov 21, 2019
Visiongain Report Provides Critical Market-led Data on the $68bn Gastrointestinal Therapeutics Market
Oct 31, 2019
Salix Announces Issuance of an Additional XIFAXAN® Patent
Oct 30, 2019
Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary
Oct 01, 2019
Bausch Health Files Lawsuit Against Sandoz For Infringement Of Patents Protecting XIFAXAN® 550 mg Tablets
Jul 16, 2019
BioPharmX Announces Steven M. Bosacki Joins the Company as Chief Operating Officer
May 17, 2019
Salix Pharmaceuticals Pledges Annual $100,000 Scholarship Program To Outstanding Students Living with GI Disease
May 14, 2019
Salix Pharmaceuticals Marks 30-Year Anniversary With Largest Showing Of Data At Digestive Disease Week
Apr 25, 2019
Global $385 Mn Traveler's Diarrhea Markets, 2019-2028
Mar 27, 2019
Traveler's Diarrhea Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Mar 18, 2019
RDD Pharma Appoints John Temperato as Chief Executive Officer
Mar 13, 2019
Salix Announces Two Methylnaltrexone Poster Presentations for Opioid-Induced Constipation at the Annual Assembly of the American Academy of Hospice and Palliative Medicine and Hospice and Palliative Nurses Association
Mar 06, 2019
Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.
Feb 26, 2019
Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.
Jan 03, 2019
NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea
Dec 12, 2018
Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.
Dec 06, 2018
ZAXINE® (rifaximin) - Now Indicated in Canada for Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)1,2
Oct 29, 2018
Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease